WAT Waters Corporation Loading...

From CRL earnings calls
Loading chart...
Top Calls
Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
All directions✓
▲ Long✓
▼ Short✓
⛔ Avoid✓
✂ Close✓
◦ Others✓
Any score✓
LOW+✓
MED+✓
HIGH✓
13:00
Aug 05 ◎
Birgit Girshick CEO, Charles River Laboratories International, Inc. CRL Q2 FY26 call
DSA bookings and book-to-bill hit their highest level in nearly four years (Q3 2022), signalling the start of an industry-wide recovery in preclinical demand, earlier than many expected. — Strong DSA demand may indicate a broader CRO recovery trend; competitors may also see improvements later in 2026.
WAT
MED

About WAT Analyst Coverage

Buzzberg tracks WAT (Waters Corporation) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Birgit Girshick.